First things first, coordinate a treatment plan with your doctor.
The most important thing to do is to talk to a doctor and initiate treatment as soon as possible. Modern antiretroviral medication has a drastically improved side effect profile, and the faster you begin treatment, the less damage the virus can do to your immune system. Gene and cell therapies which modify cells of immune system require a relatively intact population of immune cells to use as a starting material, so if you are interested in participating in a clinical trial for a therapy such as ours, it is imperative that you are proactive and listen to your doctor's advice.
Participating in a clinical trial is no small task, but if it is something that you would like to pursue, sign up for our newsletter, or follow our social media accounts. AGT103-T is currently in the final stages of a phase 1 clinical trial, and our team is making arrangements to prepare for the possibility of a phase 2 clinical trial. Should the phase 2 trial open for enrollment, AGT will be able to provide guidance on how to apply, however, drug developers like us are not allowed to select trial participants. This is a standard practice for clinical trials. Instead, the hospitals or other healthcare facilities which participate as trial sites are tasked with selecting which applicants will participate in the trial.